CDKN2A and plasma cell myeloma: Germline alterations in CDKN2A are most frequently associated with predisposition to melanoma and pancreatic cancer but some studies describe a susceptibility to neural system tumors, breast cancer, multiple myeloma, head and neck squamous cell carcinoma and sarcoma36–38.